How Long Does Postpartum Depression Last? Recovery and Relapse

Author: Angela Bogdanova · Published: October 18, 2026 · Editorial Policy

Research cluster: Cluster Perinatal and Reproductive Mental Health · Written by Artificial Sapiens

How long can postpartum depression last?

Postpartum depression can improve substantially within several months, especially when it is recognized and treated. The UK National Health Service describes improvement within roughly three to six months as common, while emphasizing that depression can last much longer. For an individual parent, the course depends on symptom severity, prior episodes, access to effective care, ongoing stressors, coexisting conditions, and the adequacy of follow-up. There is no single recovery deadline fixed by the baby's age. NHS postnatal depression guidance; ACOG treatment guideline.

Persistent symptoms are a major reason to maintain assessment beyond the early postpartum visits. In a longitudinal study of 4,866 mothers followed at four months and at one, two, and three years after birth, researchers identified several distinct trajectories: about 74.7% had consistently low symptom scores; 12.6% had initially moderate symptoms that decreased; 8.2% began with low scores that increased; and 4.5% had persistently high symptom scores. These groups describe questionnaire-based symptom patterns in a cohort, not the probability that a clinically diagnosed episode will last a specific number of years. Putnick et al., Pediatrics (2020).

An additional systematic review and meta-analysis, published in 2025, combined 32 studies involving 57,210 participants in 18 countries. It estimated a 15% prevalence of postnatal depression or elevated depressive symptoms during months 13–24 after birth, compared with 16% during the first year. The studies differed in populations, screening methods, and clinical definitions, and the wide prediction intervals reflected considerable heterogeneity. Those percentages are cross-sectional prevalence estimates, not evidence that exactly 15% of an initially depressed group remained continuously ill. Hellyer et al., International Journal of Mental Health Nursing (2025).

The central clinical principle is straightforward: improvement is possible at every stage, continuing symptoms deserve a proper evaluation, and treatment aims at sustained remission and restored functioning rather than merely reaching a particular postpartum anniversary. NIMH perinatal depression overview.

What the word “last” means in clinical research

Episode duration, symptoms, and functional recovery

A depressive episode is an interval in which symptoms and associated impairment meet clinical criteria. Symptom duration begins when the episode emerges; the date of childbirth provides a context for its onset but does not automatically determine when the disorder resolves. A person may have experienced depression during pregnancy that continues after delivery, or may develop a new episode weeks or months afterward. Modern perinatal guidance recognizes depression arising or worsening across pregnancy and the first postpartum year, even though specific diagnostic manuals employ narrower onset specifiers. ACOG screening and diagnosis guideline.

Clinical improvement is described at different levels. Response means a substantial reduction in symptoms relative to baseline. Remission means depressive symptoms have become minimal or absent by the chosen clinical standard. Functional recovery encompasses renewed capacity for self-care, meaningful connection, daily decisions, relationships, and valued activities; it may progress after symptom scores have improved. A parent may therefore report feeling better without yet sleeping reliably, enjoying activities, concentrating normally, or experiencing confidence with infant care. Conversely, someone may be meeting most outward responsibilities while remaining substantially depressed.

Longitudinal cohort studies often measure symptom scales rather than structured diagnostic interviews. Their categories such as low-stable, medium-decreasing, and high-persistent capture broad developmental patterns. They cannot precisely establish how many months a given formally diagnosed episode lasted, whether therapy began between measurement points, or whether there were periods of remission followed by new episodes. This methodological distinction is essential when interpreting population statistics. Putnick et al. (2020); Hellyer et al. (2025).

Relapse, recurrence, chronic symptoms, and residual symptoms

Relapse commonly refers to a return or worsening of the same depressive episode before stable recovery has been established. Recurrence generally describes a new depressive episode after a meaningful period of recovery. Persistent or chronic depression involves symptoms extending over a long period, while residual symptoms are problems that remain after substantial improvement. In practice, studies vary in the remission interval and diagnostic thresholds used to separate relapse from recurrence; clinical records should state what was actually observed.

The distinction affects decisions. A return of symptoms shortly after medication reduction may require reassessing a current treatment plan. A new episode after a long well interval may prompt a renewed diagnostic review and discussion of longer-term prevention. Residual insomnia, persistent loss of pleasure, agitation, and hopelessness matter because they can be associated with impairment and future deterioration. NICE depression in adults guideline, NG222.

The recovery timeline: what can happen over days, weeks, months, and years

The first two weeks: adjustment and baby blues

Emotional sensitivity, tearfulness, irritability, exhaustion, and brief mood changes may accompany the early postpartum transition. Baby blues usually settle within approximately two weeks. They occur amid sleep disruption, rapid biological adjustment, and enormous practical demands. Their presence alone does not constitute major depression. Persistent worsening mood, inability to enjoy anything, marked hopelessness, or loss of functioning should trigger assessment, including within those first two weeks when symptoms are severe. The two-week distinction is a useful guide, not permission to postpone urgently needed care. NIMH; NHS.

Weeks two through eight: recognition and initial treatment

Many clinically significant episodes become apparent during the first several weeks after delivery. NIMH describes onset for many perinatal depressive episodes within four to eight weeks postpartum. A depressed parent may experience persistently low mood, loss of interest or pleasure, excessive guilt, agitation or slowing, impaired concentration, appetite changes, disrupted sleep beyond infant-care demands, or thoughts of death. Anxiety, irritability, intrusive worries, and difficulty feeling connected may also occur. A symptom pattern is evaluated for duration, intensity, impairment, medical explanations, and psychiatric differential diagnosis; a screening questionnaire is not a diagnosis. NIMH; ACOG screening guideline.

An initial treatment plan may combine interpersonal psychotherapy, cognitive behavioral therapy, medication, and practical supports. Some individuals notice early improvements in sleep, hope, emotional regulation, or ability to initiate activities before full remission. Others need treatment adjustment, especially when the episode is severe or multiple stressors remain active. Shared decisions should include breastfeeding, prior medication response, co-occurring anxiety, and bipolar-spectrum assessment. ACOG treatment guideline; NICE antenatal and postnatal guideline.

Months two through six: a common recovery window, not a cutoff

A meaningful degree of recovery over the first three to six months is consistent with clinical guidance, but the trajectory is individualized. An active treatment plan should be reviewed when progress is inadequate. Monitoring should include severity, functioning, safety, adverse effects, obstacles to attendance, medication adherence where relevant, and practical circumstances such as unstable housing or inadequate help with infant care. A person who improves at four months may still benefit from sustained treatment and follow-up. NHS; ACOG assessment and treatment resources.

Months six through twelve: continuing and newly recognized episodes

The latter half of the first postpartum year remains clinically important. Some parents have symptoms that began soon after childbirth and persisted; others developed depression later or were not assessed earlier. Return to work, changing caregiving arrangements, infant illness, social isolation, feeding decisions, and ongoing poor sleep can influence how a parent feels. These experiences may also coincide with depression that requires treatment. A baby reaching six or twelve months does not erase maternal depression or remove the need for care. The risk of suicide and other serious psychiatric complications must be assessed whenever warning signs arise, independent of how many months have passed. ACOG screening guideline; NICE CG192.

The second and third postpartum years: persistent or later depressive symptoms

Evidence for the second year challenges the assumption that depressive morbidity ends at the child's first birthday. The 2025 synthesis identified a comparable prevalence during postpartum years one and two, although it could not always distinguish continuous illness from a newly developed depressive episode. The NIH cohort also documented a small persistent-high group and a separate group whose scores increased over time. Taken together, these findings argue for ongoing pathways to evaluation and treatment; neither a screening score nor a population prevalence figure should be presented as a precise personal prognosis. Hellyer et al. (2025); Putnick et al. (2020).

After one or two years, clinicians should still assess major depressive disorder and related conditions on their own merits. The fact that symptoms emerged around childbirth can remain clinically relevant to history, recurrence planning, family context, and treatment preferences. Effective mental health care continues regardless of whether the person meets a particular service's definition of the postpartum period.

Why some people recover faster than others

Severity and earlier psychiatric history

Severity at presentation, repeated past depressive episodes, a history of bipolar disorder, suicidal thoughts, psychiatric hospitalization, and comorbid anxiety affect prognosis and the urgency of treatment planning. Baseline symptom burden can help identify the intensity of care and follow-up needed, but it does not permit a deterministic estimate for a particular individual. The NIH trajectory study found that a previously diagnosed mood disorder was associated with the high-persistent symptom trajectory; this is an observational association, not a causal demonstration. Putnick et al. (2020).

Sleep disruption, stress, and caregiving demands

Postpartum sleep is shaped by infant feeding, pain, anxiety, household division of labor, partner support, and opportunities for uninterrupted rest. Sleep disturbance can be both a symptom of depression and a factor that maintains fatigue and emotional instability. Lack of practical assistance may compromise treatment attendance, nutrition, restorative time, and the ability to follow a care plan. Addressing these conditions is an important part of recovery, although sleep advice alone is not treatment for a severe depressive disorder.

Traumatic birth experiences, infant medical complications, previous pregnancy losses, financial insecurity, discrimination, and intimate partner violence may intensify distress. Each requires a contextual response. Such factors should be investigated with sensitivity rather than treated as evidence of personal failure or as automatic proof of a specific psychiatric diagnosis. NICE CG192.

Biological, endocrine, and medical contributors

Childbirth entails rapid endocrine change and physical recovery, but postpartum depression cannot be explained by a single universal hormonal deficiency. Research addresses interacting reproductive neurobiology, stress regulation, inflammatory signaling, individual vulnerabilities, and environmental context; mechanisms remain heterogeneous. Clinicians may also investigate postpartum thyroid disorders, anemia, medication effects, pain, sleep disorders, or other medical problems when the presentation warrants it. Finding a contributing medical condition can change the management plan without negating the psychological experience. NIMH; ACOG diagnosis guideline.

Treatment access and fit

Timely treatment, a workable therapeutic relationship, consistent follow-up, and a plan that addresses individual needs are relevant to recovery. Access can be limited by cost, waitlists, lack of childcare, transport, stigma, language barriers, and culturally mismatched services. Medication may be poorly tolerated, the first psychotherapy may be inaccessible, or an initial diagnosis may need revision. When improvement stalls, a structured reassessment is more productive than attributing the delay to a lack of effort. ACOG treatment guideline.

Recognizing progress and remission

Progress includes changes in frequency and intensity of low mood, willingness to engage, the ability to experience pleasure, concentration, appetite, and energy. It also includes practical markers: getting through daily activities with less distress, reconnecting with a partner or friend, and becoming more able to ask for help. Feeling affection for a baby is not a mandatory measure of recovery; bonding is complex and may fluctuate with exhaustion, past trauma, expectations, and family context.

Why recovery may feel uneven

Even with effective care, symptom change is rarely perfectly linear. A difficult night, an infant's illness, a work transition, or a conflict can cause a temporary setback. A short-lived bad day differs from a sustained return of depressive symptoms and impaired functioning. A useful question is whether the underlying trajectory across several weeks is improving, stable, or worsening. A clear and recurring deterioration merits contact with the treating clinician rather than waiting for a predetermined review date.

What measurement-based follow-up adds

Validated instruments such as the Edinburgh Postnatal Depression Scale (EPDS) and Patient Health Questionnaire-9 (PHQ-9) help clinicians track change when used with history and professional judgment. EPDS scores reflect answers over a defined recent interval; thresholds vary with setting and screening objective. The PHQ-9 measures depressive symptoms and their severity, but neither score establishes a diagnosis, excludes bipolar disorder, or replaces a suicide-risk evaluation. An item indicating self-harm thoughts requires prompt direct assessment. ACOG recommends monitoring response and remission with validated tools and adjusting care when clinically indicated. ACOG assessment and treatment resources; ACOG screening guideline.

Care teams can document the original symptom profile, current severity, sleep, functioning, support, medication adherence, and any new safety concerns at successive visits. This distinguishes residual symptoms from relapse and identifies emerging conditions that require a different intervention.

What treatment can change about duration

Cognitive behavioral therapy and interpersonal psychotherapy

Cognitive behavioral therapy (CBT) targets patterns of thought, behavior, avoidance, and emotional response that contribute to persistent depression. Interpersonal psychotherapy (IPT) works with grief, role transitions, interpersonal conflict, and support at a time when family and identity changes may be extensive. Both are recommended in perinatal guidelines, with treatment intensity guided by severity, history, preferences, and availability. Psychoeducation and peer support can add value, but severe or persistent depression may require more intensive structured care. NICE CG192; ACOG guideline No. 5.

A therapy course may extend for several months, and completing scheduled sessions is not the same as reaching remission. Follow-up should evaluate whether depressive symptoms, functioning, and coping improve. If a chosen intervention has provided little benefit, the clinician can revisit the working diagnosis, treatment dose or frequency, attendance barriers, comorbid conditions, and the option of combining approaches.

Antidepressants, response, and continuation

Antidepressants, especially selective serotonin reuptake inhibitors, are often used for moderate to severe depression, recurrence risk, or patient preference. Improvement generally develops over several weeks; some patients need a dose adjustment or a different medication. A 2021 Cochrane review of 11 randomized studies involving 1,016 participants found low- or very-low-certainty evidence that SSRIs may improve response and remission over placebo in postpartum depression, while emphasizing small samples and limited long-term comparative evidence. Its short-term outcomes do not establish a universal time to recovery. Brown et al., Cochrane (2021).

Medication continuation after improvement is a separate decision from the time it takes to feel better. ACOG's patient guidance notes that common antidepressants are generally continued for at least six months after symptoms improve, with individualization by episode history and relapse risk. NICE also recommends periodic reassessment when antidepressants are continued for relapse prevention. A parent who feels better in the third month should discuss the continuation phase with a prescriber instead of abruptly stopping a drug. Withdrawal effects can resemble deterioration, and stopping may permit depressive symptoms to return. ACOG on postpartum depression medication; NICE NG222.

Breastfeeding is part of an individualized discussion, including the specific medicine, infant health, the mother's symptom severity, and the risks of untreated illness. ACOG advises against withholding or discontinuing psychiatric treatment solely because someone is pregnant or lactating. Medication changes should be coordinated with the prescribing clinician. ACOG assessment and treatment resources.

Zuranolone and time-limited treatment courses

Oral zuranolone is a 14-day treatment approved in the United States for postpartum depression in adults. That short dosing course must not be confused with a guarantee that the underlying condition has permanently resolved in 14 days. Studies assess rapid reductions in depressive symptoms over short follow-up intervals, and clinical planning still requires review of symptom persistence, functioning, safety, and additional ongoing treatment where appropriate. Current ACOG guidance includes a dedicated clinical practice update published in 2026. ACOG Clinical Practice Update (2026); ACOG patient guidance.

Zuranolone can cause sedation and dizziness and requires careful attention to driving, interactions, pregnancy prevention, and infant feeding discussions. ACOG's patient advice recommends avoiding driving for 12 hours after each dose. Patients should use the current product label and clinician-specific instructions, which may change over time. The former intravenous brexanolone product was withdrawn from the US market in 2025; its evidence and historical use are distinct from currently available treatments. Federal Register: withdrawal of Zulresso approval (2025); ACOG update (2026).

Persistent depression and treatment reassessment

When depression remains substantial after an adequate trial, reassessment should consider correct diagnosis, dose and duration, medication interactions, therapeutic fit, adherence, concurrent anxiety or PTSD, bipolar-spectrum symptoms, physical illnesses, substance use, chronic stress, and safety. Evidence-based specialist options depend on clinical setting and severity. The goal is to adjust care rather than wait indefinitely for spontaneous improvement. NICE guidance for adult depression advises a structured discussion of reasons for nonresponse after an adequate initial treatment interval. NICE NG222.

When continuing symptoms call for another assessment

A parent should contact a clinician when depressive symptoms persist for more than two weeks, intensify, impair caregiving or basic self-care, or recur after an initial period of improvement. Earlier evaluation is warranted when distress is severe or safety is in doubt. Persistent symptoms three, six, twelve, or more months after childbirth merit the same rigorous clinical assessment as symptoms early after delivery. Support should not expire with the formal end of postpartum obstetric visits. NIMH; ACOG screening guideline.

Differential diagnosis: depression, bipolar illness, anxiety, trauma, and medical conditions

The evaluation may distinguish unipolar major depression from bipolar depression, posttraumatic stress following childbirth, generalized anxiety, obsessive-compulsive disorder, intrusive thoughts, grief, or adjustment-related distress. Important questions concern prior periods of unusually elevated or irritable mood, markedly increased energy, reduced need for sleep without tiredness, impulsivity, grandiosity, or psychotic symptoms. A person with bipolar disorder may need different medication planning, because antidepressant monotherapy can be inappropriate and may increase risks in selected patients. The clinician also reviews pain, thyroid symptoms, anemia, medication effects, substance use, and severe sleep deprivation. ACOG guideline No. 4; ACOG guideline No. 5.

Immediate safety: suicidality, mania, and postpartum psychosis

Thoughts of suicide, an intention to harm oneself or someone else, inability to stay safe, hallucinations, delusions, profound confusion, or escalating manic symptoms require urgent professional evaluation. Postpartum psychosis is a psychiatric emergency, often involving a rapid change in mental state and impaired reality testing; treatment commonly requires emergency psychiatric assessment and a protected care setting. A parent with such symptoms should not be left alone with an infant until an appropriate emergency team has assessed safety. In the United States, call 911 for immediate danger or 988 for crisis support. Elsewhere, contact local emergency services. ACOG screening guideline; NICE CG192.

Intrusive, unwanted, frightening thoughts can also arise in anxiety or OCD while insight remains intact and the person is distressed by the thoughts. These experiences call for respectful assessment; they are clinically different from psychotic beliefs or intentions to act. A clinician evaluates the full context, associated compulsions, insight, immediate risk, and diagnostic features. Stigma can discourage disclosure, so precise questioning matters.

Relapse after improvement: how to recognize and respond

Early signs of a return of depression

Recurrence may begin with subtle changes before a full depressive episode becomes obvious: persistent loss of interest, worsening sleep unrelated to infant needs, withdrawing from relationships, a sense of hopelessness, increasing self-criticism, low motivation, or repeated periods of tearfulness. A single difficult afternoon is common in family life; a pattern of accumulating, impairing symptoms calls for attention. Written notes on sleep, mood, treatment changes, stressors, and symptom duration can help a care team distinguish ordinary fluctuations from returning depression.

A relapse plan can identify whom to contact, what changes justify an earlier appointment, what practical support can be mobilized, and how access to urgent services works. The plan should reflect the individual's own previous symptom pattern and medical history, including any earlier mania, severe depression, or suicidality. NICE NG222.

Stopping or changing treatment

Relapse can occur while treatment is continuing or after it ends. Changing medication, missing many doses, or abruptly discontinuing a drug can complicate interpretation because discontinuation symptoms and depression recurrence can overlap. Prescribers can discuss gradual tapering, ongoing monitoring, and a plan for rapid re-evaluation. Psychological relapse-prevention work may also help people identify triggers, rebuild protective routines, and respond early when warning signs return. NICE recommends shared decisions and continuing therapy or medication when the balance of individual relapse risks and burdens supports that approach. NICE NG222.

Recurrence in a later pregnancy or after another birth

A history of postpartum depression raises concern for another episode after a later pregnancy, but it is not a prediction that recurrence is inevitable. A Danish population register study of women with no prior psychiatric history estimated subsequent postpartum affective-disorder recurrence in 15% of those initially identified through postpartum antidepressant treatment and 21% of those whose first postpartum episode required hospital contact. These estimates applied to the study's treatment-defined groups and should not be generalized to every patient, especially those with unrecorded episodes or different healthcare access. Rasmussen et al., PLOS Medicine (2017).

The same research illustrates selection effects: a treatment-defined registry captures a narrower population than a community survey or broad questionnaire. An individual risk discussion should integrate prior severity, multiple episodes, bipolar-spectrum history, treatment response, symptoms during pregnancy, support, sleep, and patient preferences. Prevention planning before another birth can include coordinated obstetric and psychiatric care, more frequent monitoring, psychotherapy, and individualized medication decisions. Evidence that antidepressants prevent recurrence in all women remains limited; the Cochrane review of preventive antidepressants included only two small trials totaling 81 participants. Cochrane prevention review.

Families, relationships, and life after symptoms improve

Depression can alter communication, intimacy, partnership roles, confidence, and the experience of infant care. As mood improves, parents may still need time to repair disrupted routines, reconnect socially, rebuild trust in their own judgment, or process distressing memories. A partner may have carried substantial caregiving responsibilities; an extended recovery plan can address both the parent's needs and the family's sustainable arrangements. Clinical follow-up can include relationship concerns and practical assistance without reducing depression to an interpersonal problem alone.

A person can feel attachment to a child throughout a depressive episode, or find emotional availability difficult during illness. Both experiences deserve sensitive exploration. Recovery is supported when parenting expectations are realistic, sleep and basic resources are addressed, and mental health symptoms receive the same legitimacy as other health problems. Where bonding concerns are persistent, parent–infant support can be discussed alongside depression treatment. NICE CG192; NIMH.

Building a follow-up and relapse-prevention plan

A useful plan begins with a clinical baseline: previous episode dates, depression severity, any suicidal thoughts, bipolar-spectrum signs, current medications and therapies, residual symptoms, and the parent's major stressors. The care team can agree on regular appointments, symptom measurement, medication or therapy review, and thresholds for early contact. A named urgent-care pathway should be documented for emergencies.

The plan should protect time for sleep, arrange realistic help with caregiving and household work, and remove barriers to treatment appointments where possible. Family members can learn how the parent's particular symptoms manifest and ask direct, supportive questions rather than relying solely on outward appearance. During a future pregnancy, proactive perinatal mental health review is appropriate for someone with a significant prior episode. ACOG guideline No. 5; NICE NG222.

Treatment decisions should be revisited at clinically meaningful points: after starting care, following a major change in symptoms, when returning to work, if breastfeeding or medication goals change, before tapering a medicine, and when planning another pregnancy. Successful recovery includes an accessible path back to care if new symptoms emerge.

Research limitations and what the evidence can establish

There is strong evidence that postpartum depression is clinically important, that evidence-based treatments are available, and that depressive symptoms can remain elevated beyond the early postpartum months. There is also robust evidence of variation in longitudinal symptom trajectories. However, the literature is less precise about the exact untreated duration of clinically diagnosed episodes, individual time-to-remission distributions, and long-term relapse rates after specific perinatal treatments. ACOG CPG No. 5; Putnick et al. (2020).

Screening studies can classify high scores as probable depression without structured diagnostic confirmation. Cross-sectional prevalence in the second postpartum year does not demonstrate that the same participants have continuously been depressed since birth. Registry studies may capture treated and more severe episodes while missing people who never obtained medical care. Trials of postpartum treatment often have short follow-up periods and fewer participants than the broader evidence base for adult major depression. Research may also underrepresent fathers and nonbirthing parents, younger parents, marginalized groups, and patients with complex psychiatric illness. These limitations matter when translating group averages into individualized care. Hellyer et al. (2025); Brown et al. (2021); Rasmussen et al. (2017).

The best-supported clinical approach combines prompt recognition, diagnosis where warranted, measurement-based treatment, attention to safety, and follow-up long enough to establish durable recovery. The question of how long postpartum depression lasts is answered most accurately by tracking the person's actual symptoms and functioning, while using population research to guide sensible expectations and continued availability of care.

Frequently asked questions

Can postpartum depression go away without treatment?

Some depressive symptoms improve over time, and not every distressed parent meets criteria for a depressive disorder. Yet the possibility of spontaneous improvement does not justify postponing assessment when symptoms persist, intensify, or impair daily life. Treatment is associated with better recovery prospects, and urgent warning signs require immediate assessment. NHS.

Is it normal to still have postpartum depression after six months?

Depressive symptoms can persist beyond six months and remain clinically relevant. Persistence deserves professional evaluation, a review of the existing plan, and attention to contributing physical and psychological conditions. Six months is not an upper limit for legitimate care. NHS; Putnick et al. (2020).

Can postpartum depression last one, two, or three years?

Yes. Studies have identified elevated depressive symptoms in the second postpartum year and a persistent-high subgroup followed through three years. The research does not imply that all such participants had an uninterrupted, formally diagnosed postpartum depressive episode. Treatment should be available whenever clinically indicated. Hellyer et al. (2025); Putnick et al. (2020).

If symptoms improve, should I stop antidepressants immediately?

Discuss continuation and any tapering plan with the prescriber. Relapse prevention may require maintaining a helpful treatment for months after improvement, and abrupt discontinuation can create symptoms that complicate assessment. ACOG discusses continuation for at least six months after improvement for commonly used antidepressants, while NICE recommends individualized review. ACOG; NICE NG222.

Does recovery mean I will never experience postpartum depression again?

Recovery from a current episode is achievable, and future episodes remain possible. A previous episode, especially one requiring more intensive treatment, warrants a prevention discussion before a subsequent pregnancy and a clear plan for early follow-up. A later episode is an opportunity for renewed evidence-based care, not a failure of the previous recovery. Rasmussen et al. (2017).

How can I tell if I am having a relapse or just a difficult week?

Look at persistence, symptom clustering, functional change, and whether the pattern resembles a prior episode. Temporary exhaustion or distress may fluctuate with circumstances; a sustained return of low mood, anhedonia, hopelessness, or impaired functioning deserves assessment. Suicidal thinking, mania, psychosis, or inability to remain safe demands urgent help regardless of how long symptoms have been present. ACOG screening guideline.

Related Articles

Postpartum Depression: Symptoms, Causes, Diagnosis, and Treatment — the clinical definition, diagnostic evaluation, and treatment foundation for postpartum depressive disorder.

Postpartum Depression Treatment: Therapy, Medication, and Recovery — evidence-based treatment choices and monitoring through recovery.

Baby Blues vs Postpartum Depression: Symptoms, Duration, and Help — an early postpartum comparison of transient mood changes and depressive illness.

Edinburgh Postnatal Depression Scale: Questions, Scores, and Limits — the role of repeated screening scores and clinical assessment.

Postpartum Psychosis: Early Warning Signs and Emergency Care — recognition and emergency pathways for postpartum psychosis.

Antidepressants While Breastfeeding: Safety Evidence and Decisions — individualized lactation and pharmacotherapy decisions.

References

American College of Obstetricians and Gynecologists. (2023a). Screening and diagnosis of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 4. Official guideline.

American College of Obstetricians and Gynecologists. (2023b). Treatment and management of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 5. https://doi.org/10.1097/AOG.0000000000005202.

American College of Obstetricians and Gynecologists. (2026). Zuranolone and brexanolone for the treatment of postpartum depression. Obstetrics & Gynecology, 147(1), e24–e28. https://doi.org/10.1097/AOG.0000000000006093.

Brown, J. V., Wilson, C. A., Ayre, K., et al. (2021). Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews, CD013560. https://doi.org/10.1002/14651858.CD013560.pub2.

Hellyer, E., Nash, K., Jones, E., et al. (2025). Postnatal depression beyond 12 months: A systematic review and meta-analysis. International Journal of Mental Health Nursing, 34(2), e70018. https://doi.org/10.1111/inm.70018.

Molyneaux, E., Telesia, L. A., Henshaw, C., Boath, E., Bradley, E., & Howard, L. M. (2018). Antidepressants for preventing postnatal depression. Cochrane Database of Systematic Reviews, CD004363. https://doi.org/10.1002/14651858.CD004363.pub3.

National Health Service. (n.d.). Postnatal depression. Official NHS guidance.

National Institute for Health and Care Excellence. (2014, updated). Antenatal and postnatal mental health: Clinical management and service guidance (CG192). Official recommendations.

National Institute for Health and Care Excellence. (2022, updated). Depression in adults: Treatment and management (NG222). Official recommendations.

National Institute of Mental Health. (n.d.). Perinatal depression. Official NIMH overview.

Putnick, D. L., Sundaram, R., Bell, E. M., et al. (2020). Trajectories of maternal postpartum depressive symptoms. Pediatrics, 146(5), e20200857. https://doi.org/10.1542/peds.2020-0857.

Rasmussen, M.-L. H., Strøm, M., Wohlfahrt, J., Videbech, P., & Melbye, M. (2017). Risk, treatment duration, and recurrence risk of postpartum affective disorder in women with no prior psychiatric history: A population-based cohort study. PLOS Medicine, 14(9), e1002392. https://doi.org/10.1371/journal.pmed.1002392.

U.S. Food and Drug Administration. (2025). Sage Therapeutics, Inc.; withdrawal of approval of a new drug application for Zulresso (brexanolone) solution, 100 milligrams/20 milliliters. Federal Register, 90, 12162–12163. Official notice.